Quoin pharmaceuticals provides corporate update and announces first quarter 2024 financial results

Fda clearance to recruit teens in both on-going netherton syndrome clinical studies u.s. and international patent filed for novel netherton syndrome combination product cash runway extended into late 2025 ashburn, va., may 09, 2024 (globe newswire) -- quoin pharmaceuticals ltd.
QNRX Ratings Summary
QNRX Quant Ranking